High definition transcranial direct current stimulation as an intervention for cognitive deficits in Alzheimer's dementia: A randomized controlled trial.

IF 7.8 Q2 BUSINESS The Journal of Prevention of Alzheimer's Disease Pub Date : 2025-02-01 Epub Date: 2025-01-01 DOI:10.1016/j.tjpad.2024.100023
Christian LoBue, Hsueh-Sheng Chiang, Amber Salter, Shawn McClintock, Trung P Nguyen, Rebecca Logan, Eric Smernoff, Seema Pandya, John Hart
{"title":"High definition transcranial direct current stimulation as an intervention for cognitive deficits in Alzheimer's dementia: A randomized controlled trial.","authors":"Christian LoBue, Hsueh-Sheng Chiang, Amber Salter, Shawn McClintock, Trung P Nguyen, Rebecca Logan, Eric Smernoff, Seema Pandya, John Hart","doi":"10.1016/j.tjpad.2024.100023","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Recent disease-modifying treatments for Alzheimer's disease show promise to slow cognitive decline, but show no efficacy towards reducing symptoms already manifested.</p><p><strong>Objectives: </strong>To investigate the efficacy of a novel noninvasive brain stimulation technique in modulating cognitive functioning in Alzheimer's dementia (AD).</p><p><strong>Design: </strong>Pilot, randomized, double-blind, parallel, sham-controlled study SETTING: Clinical research site at UT Southwestern Medical Center PARTICIPANTS: Twenty-five participants with clinical diagnoses of AD were enrolled from cognition specialty clinics.</p><p><strong>Intervention: </strong>Treatment consisted of high definition transcranial direct current stimulation (HD-tDCS) delivered for 20 min over the medial prefrontal cortex. Ten sessions of sham, 1 mA, or 2 mA stimulation were received.</p><p><strong>Measurements: </strong>Cognitive outcomes were measured at baseline, after the last HD-tDCS session, and 8-weeks post-treatment. The primary outcome was change in total learning and delayed recall on the Rey Auditory Verbal Learning Test (RAVLT) immediately post-treatment and at 8-weeks. Secondary outcomes included measures of language, processing speed, and executive functioning. A multi-stage approach was used to examine cognitive outcomes, which included evaluation of effect sizes, statistical effects, and rate of clinically meaningful responses.</p><p><strong>Results: </strong>In this pilot trial, no statistically significant differences on cognitive outcomes were found between sham and active HD-tDCS immediately post-treatment (p's > 0.05). However, moderate-to-large effect sizes were identified for enhanced RAVLT total learning (Cohen's d = 0.69-0.93) and phonemic fluency (d = 1.08-1.49) for both active HD-tDCS conditions compared to sham, with rates of clinically relevant improvement between 25 and 33%. Meaningful enhancement persisted to 8 weeks only for the 1 mA condition.</p><p><strong>Conclusions: </strong>Multiple sessions of HD-tDCS over the medial prefrontal cortex appears to have potential to produce meaningful cognitive enhancements in a proportion of patients having AD with improvements maintained for at least 8 weeks in some.</p><p><strong>Trial registration information: </strong>ClinicalTrials.gov (NCT05270408). Registered December 30, 2021.</p>","PeriodicalId":22711,"journal":{"name":"The Journal of Prevention of Alzheimer's Disease","volume":"12 2","pages":"100023"},"PeriodicalIF":7.8000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11895854/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of Prevention of Alzheimer's Disease","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.tjpad.2024.100023","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"BUSINESS","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Recent disease-modifying treatments for Alzheimer's disease show promise to slow cognitive decline, but show no efficacy towards reducing symptoms already manifested.

Objectives: To investigate the efficacy of a novel noninvasive brain stimulation technique in modulating cognitive functioning in Alzheimer's dementia (AD).

Design: Pilot, randomized, double-blind, parallel, sham-controlled study SETTING: Clinical research site at UT Southwestern Medical Center PARTICIPANTS: Twenty-five participants with clinical diagnoses of AD were enrolled from cognition specialty clinics.

Intervention: Treatment consisted of high definition transcranial direct current stimulation (HD-tDCS) delivered for 20 min over the medial prefrontal cortex. Ten sessions of sham, 1 mA, or 2 mA stimulation were received.

Measurements: Cognitive outcomes were measured at baseline, after the last HD-tDCS session, and 8-weeks post-treatment. The primary outcome was change in total learning and delayed recall on the Rey Auditory Verbal Learning Test (RAVLT) immediately post-treatment and at 8-weeks. Secondary outcomes included measures of language, processing speed, and executive functioning. A multi-stage approach was used to examine cognitive outcomes, which included evaluation of effect sizes, statistical effects, and rate of clinically meaningful responses.

Results: In this pilot trial, no statistically significant differences on cognitive outcomes were found between sham and active HD-tDCS immediately post-treatment (p's > 0.05). However, moderate-to-large effect sizes were identified for enhanced RAVLT total learning (Cohen's d = 0.69-0.93) and phonemic fluency (d = 1.08-1.49) for both active HD-tDCS conditions compared to sham, with rates of clinically relevant improvement between 25 and 33%. Meaningful enhancement persisted to 8 weeks only for the 1 mA condition.

Conclusions: Multiple sessions of HD-tDCS over the medial prefrontal cortex appears to have potential to produce meaningful cognitive enhancements in a proportion of patients having AD with improvements maintained for at least 8 weeks in some.

Trial registration information: ClinicalTrials.gov (NCT05270408). Registered December 30, 2021.

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
高清经颅直流电刺激作为阿尔茨海默氏症痴呆患者认知障碍的干预措施:随机对照试验
背景:最近对阿尔茨海默病的疾病改善治疗显示出减缓认知能力下降的希望,但对减轻已经表现出来的症状没有疗效。目的:研究一种新的无创脑刺激技术对阿尔茨海默氏痴呆(AD)认知功能的调节作用。设计:试点、随机、双盲、平行、假对照研究设置:德克萨斯大学西南医学中心临床研究点参与者:从认知专科诊所招募25名临床诊断为AD的参与者。干预:治疗包括高清晰度经颅直流电刺激(HD-tDCS)在内侧前额叶皮层传递20分钟。接受10次假、1 mA或2 mA的刺激。测量方法:在基线、最后一次HD-tDCS治疗后和治疗后8周测量认知结果。主要结果是治疗后立即和8周的Rey听觉言语学习测试(RAVLT)的总学习和延迟回忆的变化。次要结果包括语言、处理速度和执行功能的测量。采用多阶段方法检查认知结果,包括效应大小、统计效应和临床有意义反应率的评估。结果:在本先导试验中,假手术组和活动性HD-tDCS治疗后立即认知结局无统计学差异(p < 0.05)。然而,与假手术相比,在两种活跃的HD-tDCS条件下,RAVLT总学习(Cohen’s d = 0.69-0.93)和音素流畅性(d = 1.08-1.49)都得到了中等到较大的效果,临床相关的改善率在25%到33%之间。仅在1ma条件下,有意义的增强持续到8周。结论:在部分AD患者中,在前额叶内侧皮层进行多次HD-tDCS似乎有可能产生有意义的认知增强,其中一些患者的改善维持了至少8周。试验注册信息:ClinicalTrials.gov (NCT05270408)。注册日期:2021年12月30日。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
The Journal of Prevention of Alzheimer's Disease
The Journal of Prevention of Alzheimer's Disease Medicine-Psychiatry and Mental Health
CiteScore
9.20
自引率
0.00%
发文量
0
期刊介绍: The JPAD Journal of Prevention of Alzheimer’Disease will publish reviews, original research articles and short reports to improve our knowledge in the field of Alzheimer prevention including: neurosciences, biomarkers, imaging, epidemiology, public health, physical cognitive exercise, nutrition, risk and protective factors, drug development, trials design, and heath economic outcomes.JPAD will publish also the meeting abstracts from Clinical Trial on Alzheimer Disease (CTAD) and will be distributed both in paper and online version worldwide.We hope that JPAD with your contribution will play a role in the development of Alzheimer prevention.
期刊最新文献
Integrative SMR prioritizes oxidative stress-related regulatory genes for Alzheimer's disease with brain-tissue validation. Corrigendum to "Lecanemab for treatment of individuals with early Alzheimer's Disease (AD) who are apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotes" [The Journal of Prevention of Alzheimer's Disease (2026) 100507]. Living arrangements and cognitive resilience in aging: unraveling distinct pathways through plasma biomarkers. Validation of a novel cognitive-functional outcome measure optimized for early Alzheimer's Disease: Evidence from the VIVA-MIND trial. Donanemab therapy in Alzheimer's disease with mild cognitive impairment: Convergent amyloid, tau, and plasma biomarker normalization with cognitive improvement.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1